Genmab A/S Major Shareholder Announcement: Orbis Investment Management Reduces Stake Below 5%

On June 15, 2026, Genmab A/S filed a Form 6-K reporting a major shareholder announcement regarding Orbis Investment Management Limited. According to the filing, as of June 12, 2026, Orbis Investment Management Limited (controlled by the Allan & Gill Gray Foundation) reduced its holding in Genmab A/S to below the 5% threshold. Specifically, Orbis now controls 3,112,476 shares, representing 4.9917% of the total share capital and voting rights in the company. This is a decrease from its previous position of 5.0783%. The notification was made in accordance with Section 30 of the Danish Capital Markets Act. The filing includes the standard form for notification of major holdings, detailing the chain of controlled undertakings through which the shares are held, including Orbis Allan Gray Limited and Orbis Holdings Limited. No upcoming clinical trial results or other material corporate developments were mentioned in this regulatory filing.